Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
MassMutual Private Wealth and Trust FSB raised its position in Amgen Inc. (NASDAQ: AMGN) by 105.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,514 shares of the medical research company's stock after purchasing an additional 6,947 shares during
Ferguson Wellman Capital Management Inc. boosted its holdings in Amgen Inc. (NASDAQ: AMGN) by 4.8% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 259,022 shares of the medical research company's stock after acquiring an additional 11,950 shares during
Argent Capital Management LLC lowered its position in shares of Amgen Inc. (NASDAQ: AMGN) by 3.5% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 69,486 shares of the medical research company's stock after selling 2,546 shares during the quarter. Amgen comprises 0.2% of Argent
Amgen offers a diversified portfolio of established therapies across oncology and inflammation supported by robust cash flow. Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market and is expanding into high-growth gene therapies.
On September 29, 2026, Amgen Inc (AMGN) shares rose 1.3% to a current price of $423.64, within a 52-week range of $274.02 to $447.03. This price movement reflec
Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.